CVRx, Inc. (NASDAQ:CVRX) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC trimmed its holdings in shares of CVRx, Inc. (NASDAQ:CVRX) by 10.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 403,054 shares of the company’s stock after selling 49,505 shares during the period. Emerald Advisers LLC’s holdings in CVRx were worth $3,551,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC bought a new stake in CVRx during the third quarter worth approximately $108,000. Rhumbline Advisers increased its position in shares of CVRx by 28.8% during the 2nd quarter. Rhumbline Advisers now owns 17,260 shares of the company’s stock valued at $207,000 after purchasing an additional 3,863 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of CVRx in the 2nd quarter worth $218,000. International Assets Investment Management LLC acquired a new stake in shares of CVRx in the third quarter valued at $338,000. Finally, FourWorld Capital Management LLC bought a new position in CVRx during the first quarter valued at about $374,000. 75.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CVRX has been the topic of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target (up from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Canaccord Genuity Group increased their target price on shares of CVRx from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Lake Street Capital lifted their price target on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Craig Hallum dropped their price target on CVRx from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $14.00 price objective on shares of CVRx in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, CVRx has an average rating of “Moderate Buy” and a consensus price target of $15.00.

CVRx Stock Up 2.1 %

CVRX stock opened at $13.40 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 10.08 and a quick ratio of 8.85. The firm has a market capitalization of $291.93 million, a P/E ratio of -4.96 and a beta of 1.15. CVRx, Inc. has a 52-week low of $6.40 and a 52-week high of $33.13. The company’s 50 day simple moving average is $9.15 and its 200-day simple moving average is $9.49.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative return on equity of 88.85% and a negative net margin of 123.75%. The firm had revenue of $13.37 million for the quarter, compared to analysts’ expectations of $13.28 million. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. As a group, equities research analysts anticipate that CVRx, Inc. will post -2.59 EPS for the current year.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.